IRF3 and neoplasm: Indeed, following IR of tumor cells, the cGAS-STING-IRF3-type I IFN cascade activates DCs, which leads to activation of the adaptive immune response via priming of downstream effector cancer-specific T cell recognition (CD8+) as well as lysing tumor cells locally and at distant sites [299,300,303].